Published in Br J Dermatol on May 01, 2004
Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol (2010) 1.06
Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) (2013) 0.91
Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood (2016) 0.85
Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood (2014) 0.82
On the possible relationship between staphylococcal superantigens and increased Vbeta5.1 usage in cutaneous T-cell lymphoma. Br J Dermatol (2005) 0.78
Superantigens increase the survival of mice bearing T cell lymphomas by inducing apoptosis of neoplastic cells. PLoS One (2010) 0.77
Detection of Chlamydophila pneumoniae and human herpesvirus 8 in primary cutaneous anaplastic large-cell lymphoma: a case report. Infect Agent Cancer (2013) 0.76
Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection. Infect Agent Cancer (2016) 0.75
Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51
Exact prediction of a natural T cell epitope. Eur J Immunol (1991) 2.90
Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol (1996) 2.70
Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64
T-cell epitope mapping by flow cytometry. Nat Med (1998) 2.56
Detection and differentiation of fungi in clinical specimens using polymerase chain reaction (PCR) amplification and restriction enzyme analysis. J Med Vet Mycol (1993) 2.47
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81
Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature (1992) 1.76
Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol (1999) 1.67
A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8+ T-cell clone. Proc Natl Acad Sci U S A (1993) 1.63
Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer (1996) 1.59
Organization of the monocyte/macrophage system of normal human skin. J Invest Dermatol (1990) 1.58
Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.56
Is there an interaction between interleukin-10 and interleukin-22? Genes Immun (2005) 1.54
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis (2005) 1.47
Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. Br J Dermatol (1998) 1.47
Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood (1999) 1.47
Identification of common dermatophytes (Trichophyton, Microsporum, Epidermophyton) using polymerase chain reactions. Br J Dermatol (1998) 1.44
T-cell receptor and immunoglobulin gene rearrangements in cutaneous T-cell-rich pseudolymphomas. J Invest Dermatol (1990) 1.43
An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries. Immunogenetics (2000) 1.42
The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol (2000) 1.42
A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol (2007) 1.42
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest (1998) 1.40
Development of a solid phase enzyme immunoassay for the detection of anti-Ro autoantibodies. Scand J Rheumatol (1991) 1.39
Verrucosis of hands and feet in a patient with combined immune deficiency. J Am Acad Dermatol (1997) 1.39
Induction of regulatory T-lymphocyte responses by liposomes carrying major histocompatibility complex molecules and foreign antigen. Nature (1985) 1.34
Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol (2007) 1.28
Primary carcinoma of ectopic axillary breast tissue. J Eur Acad Dermatol Venereol (2006) 1.26
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol (2005) 1.25
A continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res (1987) 1.23
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol (2007) 1.21
Sclerotherapy for treatment of hemangiomas. Dermatol Surg (2000) 1.19
Candida africana sp. nov., a new human pathogen or a variant of Candida albicans? Mycoses (2001) 1.14
Hair follicles--an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité -Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol (2008) 1.12
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene (2006) 1.12
Sunscreen application at the beach. J Cosmet Dermatol (2004) 1.12
Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2, -DQA1*0201, -DQB1*0303 extended haplotype. J Invest Dermatol (1993) 1.12
CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol (2006) 1.10
Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 1.09
Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol (1993) 1.08
Peripheral blood T cell clonality in mycosis fungoides -an independent prognostic marker? J Invest Dermatol (2000) 1.08
Contact urticaria and dermatitis from self-adhesive pads. Contact Dermatitis (1985) 1.08
Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol (1998) 1.07
Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries. J Exp Med (1995) 1.05
Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res (2000) 1.05
Case report. Osteomyelitis caused by high resistant Candida guilliermondii. Mycoses (1999) 1.04
Adhesion molecule mapping in normal human skin. Arch Dermatol Res (1989) 1.04
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 1.04
Distribution of bacteria in the epidermal layers and hair follicles of the human skin. Skin Pharmacol Physiol (2011) 1.03
A family study of atopic dermatitis. Clinical and genetic characteristics of 188 patients and 2,151 family members. Arch Dermatol Res (1990) 1.01
Online lectures for students in dermatology: a replacement for traditional teaching or a valuable addition? J Eur Acad Dermatol Venereol (2009) 1.01
Very low monocytic HLA-DR expression indicates high risk of infection--immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med (1995) 1.00
Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol (1996) 1.00
Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol (2003) 0.99
Dimethyl sulfoxide as additive in ready-to-use reaction mixtures for real-time polymerase chain reaction analysis with SYBR Green I dye. Anal Biochem (2001) 0.99
Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Leukemia (2011) 0.99
Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology (2009) 0.99
Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses (1996) 0.99
Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: a population- and family-based study. J Invest Dermatol (1996) 0.98
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia (2002) 0.98
Molecular basis for the recognition of two structurally different major histocompatibility complex/peptide complexes by a single T-cell receptor. Proc Natl Acad Sci U S A (1996) 0.97
Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood (1997) 0.97
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol (1999) 0.95
Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer (2000) 0.95
In vivo methods for the analysis of the penetration of topically applied substances in and through the skin barrier. Int J Cosmet Sci (2012) 0.94
Analysis of a naturally occurring HLA class I-restricted viral epitope. Immunology (1994) 0.94
Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol (2010) 0.94
Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases. J Invest Dermatol (1994) 0.93
Common pathogenetic pathways in allergic and irritant contact dermatitis. J Invest Dermatol (1992) 0.93
Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol (1997) 0.93
The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res (2009) 0.93
Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. Br J Dermatol (2003) 0.93
Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart. Genes Immun (2004) 0.92
Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer (1995) 0.92
Tolerance to amino acid variations in peptides binding to the major histocompatibility complex class I protein H-2Kb. J Biol Chem (1995) 0.91
Combined laser tweezers and dielectric field cage for the analysis of receptor-ligand interactions on single cells. Electrophoresis (2001) 0.91
Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol (2004) 0.91
An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids. J Immunol Methods (1992) 0.91
Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta (2000) 0.91
Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol (2003) 0.91
In vitro generation of mast cell-like cells from human peripheral mononuclear phagocytes. Int Arch Allergy Appl Immunol (1983) 0.90
Follicular penetration of topically applied caffeine via a shampoo formulation. Skin Pharmacol Physiol (2007) 0.90
SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia. Leukemia (1993) 0.90